Royalty Pharma Reports Second Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Royalty Pharma plc (RPRX) Reports Q2 Revenue of $555 Million
August 11, 2021 7:35 AM EDTRoyalty Pharma plc (NASDAQ: RPRX) reported Q2 revenue of $555 million, versus $511 million reported last year.
Increased 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,080 to $2,120 millionFor earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
... More